Chemotherapy in Women with Breast Cancer
Authors: Linda C. Harlan, Limin X. Clegg, Joan L. Warren
Journal: Annals of Internal Medicine (2003)

Letters18 November 2003Chemotherapy in Women with Breast CancerLinda C. Harlan, PhD, Limin X. Clegg, PhD, and Joan L. Warren, PhDLinda C. Harlan, PhDFrom National Cancer Institute; Bethesda, MD 20852.Search for more papers by this author, Limin X. Clegg, PhDFrom National Cancer Institute; Bethesda, MD 20852.Search for more papers by this author, and Joan L. Warren, PhDFrom National Cancer Institute; Bethesda, MD 20852.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-139-10-200311180-00025 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Du and colleagues (1) used data from the New Mexico SEER tumor registry from 1991 to 1997 to assess use of chemotherapy among women with early-stage breast cancer. They concluded that there is a considerable discrepancy between the NIH Consensus Conference recommendations and community-based practice. However, much of this discrepancy may reflect low ascertainment of chemotherapy by the SEER registries.Because the National Cancer Institute recognizes that chemotherapy is underreported in SEER data, it funds Patterns of Care (POC) studies, in which SEER registries verify with the treating physicians the chemotherapy provided for a sample of cases. ...References1. Du XL, Key CR, Osborne C, Mahnken JD, Goodwin JS. Discrepancy between consensus recommendations and actual community use of adjuvant chemotherapy in women with breast cancer. Ann Intern Med. 2003;138:90-7. [PMID: 12529090] LinkGoogle Scholar2. Harlan LC, Abrams J, Warren JL, Clegg L, Stevens J, Ballard-Barbash R. Adjuvant therapy for breast cancer: practice patterns of community physicians. J Clin Oncol. 2002;20:1809-17. [PMID: 11919238] CrossrefMedlineGoogle Scholar3. Mariotto A, Feuer EJ, Harlan LC, Wun LM, Johnson KA, Abrams J. Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999. J Natl Cancer Inst. 2002;94:1626-34. [PMID: 12419789] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Linda C. Harlan, PhD; Limin X. Clegg, PhD; Joan L. Warren, PhDAffiliations: From National Cancer Institute; Bethesda, MD 20852. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoDiscrepancy between Consensus Recommendations and Actual Community Use of Adjuvant Chemotherapy in Women with Breast Cancer Xianglin L. Du , Charles R. Key , Cynthia Osborne , Jonathan D. Mahnken , and James S. Goodwin Chemotherapy in Women with Breast Cancer Xianglin L. Du and Charles R. Key Chemotherapy in Women with Breast CancerThe EditorsChemotherapy in Women with Breast Cancer James Liebmann , Clark Haskins , Barbara McAneny , Richard Giudice , Douglas Clark , and Natalie Marshall Metrics Cited byFeasibility of Capturing Cancer Treatment Data in the Utah All-Payer Claims DatabaseConcordance of hospital-based cancer registry data with a clinicians' database for breast cancerComorbidity and survival of Danish breast cancer patients from 1995 to 2005Information on chemotherapy and hormone therapy from tumor registry had moderate agreement with chart reviewsGeographic association between mammography use and mortality reduction in the US 18 November 2003Volume 139, Issue 10Page: 868KeywordsAge groupsBreast cancerCancer chemotherapyChemotherapySurveillance Epidemiology and End Results ePublished: 18 November 2003 Issue Published: 18 November 2003 Copyright & PermissionsCopyright © 2003 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...